

1. **R Kantor**, M Salai, A Ganel. Orthopedic long-term aspects of bladder extrophy. *Clinical Orthopedics and Related Research*, 1997; 335: 240-245.
2. **R Kantor**, A Barzilai, D Varon, U Martinowitz, J Gershoni. Prevalence of a CCR5 Gene 32-bp Deletion in an Israeli Cohort of HIV-1-Infected and Uninfected Hemophilia Patients. *Journal of Human Virology* 1998; 4: 299-301.
3. **R Kantor**, J Gershoni. CCR5 - The HIV Coreceptor Now In Israel. *Harefua* 1999; 137:405-409.
4. **R Kantor**, R Pauzner, L Pali, Z Farfel. High alkaline phosphatase in subacute thyroiditis. *Harefua* 1999; 136: 599-602.
5. **R Kantor**, J Gershoni. Distribution of the CCR5 gene 32-Base Pair Deletion in Israeli Ethnic Groups. *Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology* 1999; 20: 81-84.
6. **R Kantor**, H Mayan, D Varon. Acquired Hemophilia. *Harefua*, 2000; 138: 860-4.
7. **R Kantor**, H Mayan, N Reichert, Z Farfel. Kaposi's sarcoma post lung transplantation in a Sepharadi Jewish woman. *Dermatology* 2000; 200: 49-50.
8. RW Shafer, **R Kantor**, M Gonzales. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. *AIDS Reviews* 2000; 2: 211-228.
9. **R Kantor**, H Mayan, L Puritz, D Varon, Z Farfel. Acquired Hemophilia Masked by Warfarin Therapy. *Am J Med Sci* 2000;319: 197-201.
10. **R Kantor**, R Machakeno, M Gonzales, K Dupnik, J Schapiro, R W Shafer. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: An Expanded Data Model Integrating Natural Language Text and Sequence Analysis. *Nucleic Acids Research* 2001; 29: 296-299.
11. H Mayan, **R Kantor**, U Rimon, N Golubev, Z Heyman, E Goshen, B Shalmon, P Weiss. Fatal liver infarction after transjugular intrahepatic portosystemic shunt procedure. *Liver* 2001; 21:361 (case report).
12. **R Kantor**, R Pauzner, N Golubev, A Shinfeld, Z Farfel, A Smolinski. Ascending aortic pseudoaneurysm following coronary bypass in a hemodialysis patient with FUO. *Journal of Cardiovascular Surgery* 2001;42:633-4.
13. H Mayan, **R Kantor**, A Volner, Z Farfel. Acute respiratory failure with massive pulmonary infiltrates six weeks after coronary artery bypass operation. *Israel Medical Association Journal* 2001; 3: 67-68.
14. H Mayan, **R Kantor**, Z Farfel. The Trans Tubular Potassium Gradient in patients with drug-induced hyperkalemia. *Nephron* 2001; 89: 56-61.
15. **R Kantor**, JW Fessel, A Zolopa, D Israelski, N Shulman, J Montoya, M Harbour, J Schapiro, RW Shafer. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. *Antimicrobial Agents and Chemotherapy* 2002; 46:1086-92.
16. **R Kantor**, L Zijenah, RW Shafer, S Mutetwa, E Johnston, R Lloyd, A von Lieven, D Israelski D Katzenstein. HIV-1 subtype C reverse transcriptase and protease genotypes in patients from Zimbabwe failing antiretroviral therapy. *AIDS Research and Human Retroviruses* 2002; 18: 1407-13.
17. M Gonzales, TD Wu, J Taylor, I Belitskaya, **R Kantor**, D Israelski, S Chou, A Zolopa, WJ Fessel, RW Shafer. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. *AIDS* 2003; 17: 791-9.
18. **R Kantor**, D Katzenstein. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. *AIDS Reviews* 2003; 5: 25-35.
19. M Peleg, **R Kantor**. Approaches for guideline versioning using GLIF. *AMIA Annual Symposium Proceedings*. 2003:509-13.
20. TD Wu, CA Schiffer, M Gonzales, J Taylor, **R Kantor**, S Chou, D Israelski, A Zolopa, JW Fessel, RW Shafer. Mutation Patterns and Structural Correlates in HIV-1 Protease Following Varying Degrees of Protease Inhibitor Treatment. *Journal of Virology* 2003; 77: 4836-47.
21. SY Rhee, MJ Gonzales, **R Kantor**, BJ Betts, J Ravela, RW Shafer. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database. *Nucleic Acids Research* 2003; 31: 298-303.

22. E Johnston, L Zijenah, S Mutetwa, **R Kantor**, C Kittinunvorakoon, D Katzenstein. High Frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C infected patients receiving antiretroviral treatment. *Journal of Virology* 2003; 77: 7682-7688.
23. **R Kantor**, M Bakhanashvili, A Achiron. The Clinical and prognostic implications of a mutant CCR5 gene in multiple sclerosis patients. *Neurology* 2003; 61: 238-240.
24. **R Kantor**, RW Shafer, S Follansbee, J Taylor, D Shilane, L Hurley, DP Nguyen, D Katzenstein, WJ Fessel. Evolution of drug resistance in HIV-1 among persons failing antiretroviral therapy. *AIDS* 2004;18:1503-11.
25. **R Kantor**, D Katzenstein. Drug resistance in non-subtype B HIV-1. *Journal of Clinical Virology* 2004;29:152-9.
26. Akinsete, D Hirigoyen, C Cartwright, R Schut, **R Kantor**, K Henry. K103N mutation in antiretroviral therapy (ART) naïve African patients infected with HIV-1. *Clinical Infectious Diseases* 2004; 39:575-8.
27. P Balakrishnan, N Kumarasamy, **R Kantor**, S Solomon, S Vidya, KH.Mayer, M Newstein, SP Thyagarajan, D Katzenstein, B Ramratnam. HIV-1 genotypic variation in an antiretroviral treatment naïve population in South India. *Antiretroviral Research and Human Retroviruses* 2005; 21: 301-5.
28. **R Kantor**, D Katzenstein, B Efron, AP Carvalho, B Wynhoven, M Soares, P Cane, J Clarke, J Snoeck, C Pillay, S Sirivichayakul, K Ariyoshi, A Holguin, P Weidle, H Rudich, R Rodrigues, MB Bouzas, P Cahn, L Brigido, Z Grossman, V Soriano, W Sugiura, P Phanuphak, L Morris, AM Vandamme, J Weber, D Pillay, A Tanuri, R Harrigan, R Camacho, J Schapiro RW Shafer. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotypic evolution: results of a global collaboration. *PLOS Medicine* 2005; 2:e112.
29. EJ Lee, **R Kantor**, L Zijenah, W Sheldon, P Mateta, E Johnston, J Wells, A Shetty, H Coovadia, Y Maldonado, SA Jones, C Contag, M Bassett, D Katzenstein. Breast-milk shedding of drug resistant subtype C HIV-1 among women receiving single dose nevirapine. *Journal of Infectious Diseases* 2005; 192:1260-4.
30. J Snoeck, **R Kantor**, RW Shafer, K Van Laethem, K Deforche, AP Carvalho, B Wynhoven, MA Soares, P Cane, J Clarke, C Pillay, S Sirivichayakul, K Ariyoshi, A Holguin, H Rudich, R Rodrigues, MB Bouzas, F Brun-Vézinet, C Reid, P Cahn, LF Brigido, Z Grossman, V Soriano, W Sugiura, P Phanuphak, L Morris, J Weber, D Pillay, A Tanuri, RP Harrigan, R Camacho, JM Schapiro, D Katzenstein and AM Vandamme. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of the Human Immunodeficiency Virus are subtype dependent. *Antimicrobial Agents and Chemotherapy*, 2006; 50:694-701.
31. **R Kantor**. Impact of HIV-1 *pol* diversity on drug resistance and its clinical implications. *Current Opinion in Infectious Diseases* 2006;19:594-606.
32. SY Rhee, **R Kantor**, D Katzenstein, R Camacho, L Morris, D Pillay, Z Grossman, P Phanuphak, P Cahn, V Soriano, LF Brigido, AM Vandamme, A Tanuri, J Weber, W Sugiura, JM Schapiro and RW Shafer. HIV-1 Pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. *AIDS* 2006;20:643-51.
33. K Deforche, R Camacho, Z Grossman, T Silander, MA Soares, Y Moreau, RW Shafer, K Van Laethem, AP Carvalho, B Wynhoven, P Cane, J Snoeck, J Clarke, S Sirivichayakul, K Ariyoshi, A Holguin, H Rudich, R Rodrigues, MB Bouzas, P Cahn, LF Brigido, V Soriano, W Sugiura, P Phanuphak, L Morris, J Weber, D Pillay, A Tanuri, PR Harrigan, JM Shapiro, DA Katzenstein, **R Kantor**, AM Vandamme. Bayesian network analysis of resistance pathways against protease inhibitors. *Infection, Genetics and Evolution*. 2006; 7:382-90.
34. K Deforche, T Silander, R Camacho, Z Grossman, MA Soares, K Van Laethem, **R Kantor**, Y Moreau, AM Vandamme. Analysis of HIV-1 *pol* sequences using Bayesian Networks: implications for drug resistance. *Bioinformatics*, 2006; 22:2975-9.
35. S Kassaye, E Lee, **R Kantor**, E Johnston, M Winters, L Zijenah, P Mateta, D Katzenstein. Evolution of drug resistance in plasma and breast-milk after single-dose nevirapine in HIV-1

- subtype C: comparison of population sequencing and clonal analyses. *AIDS Research and Human Retroviruses* 2007;23:1055-61.
36. **R Kantor**, J Gershoni. HIV/AIDS and the Genetic Revolution - Custom Tailoring Antiretroviral Regimens in the Management of HIV. *The International Journal for Healthcare Technology and Management* 2007;7:478-491.
 37. K Deforche, RJ Camacho, Z Grossman, MA Soares, K Van Laethem, DA Katzenstein, PR Harrigan, **R Kantor**, R Shafer, AM Vandamme, on behalf of the non-B workgroup. Bayesian network analyses of resistance pathways against efavirenz and nevirapine. *AIDS* 2008; 22:2107-15.
 38. V Pillay, C Pillay, **R Kantor**, F Venter, L Levin, L Morris. HIV-1 subtype C drug resistance profiles among South African patients failing anti-retroviral therapy. *AIDS Research and Human Retroviruses* 2008;24:1449-54.
 39. PA Chan, SE Wakeman, T Flanigan, S Cu-Uvin, E Kojic, **R Kantor**. HIV-2 diagnosis and quantification in high-risk patients. *AIDS Research and Therapy* 2008;5:18.
 40. SG Kassaye, E Johnston, B McColgan, **R Kantor**, Lynn Zijenah, D Katzenstein. Envelope co-receptor tropism, drug resistance, and viral evolution among subtype C HIV-1 infected individuals receiving non-suppressive antiretroviral therapy. *JAIDS* 2009;50:9-18.
 41. D Bennett, R Camacho, D Otelea, D Kuritzkes, H Fleury, M Kiuchi, W Heneine, **R Kantor**, M Jordan, V Miller, J Schapiro, AM Vandamme, P Sandstrom, CAB Boucher, DVD Vijver, SY Rhee, T Liu, D Pillay, R Shafer. Drug resistance mutations for surveillance of transmitted HIV-1 drug resistance: 2009 update. *PLOS One* 2009;4:1-8.
 42. S Saravanan., M Vidya., P Balakrishanan, N Kumarasamy, SS Solomon, S Solomon, **R Kantor**, D Katzenstein, B Ramratnam, KH Mayer. Comparative Evaluation of Two Human Immunodeficiency Virus Genotyping systems: the Viroseq™ HIV-1 genotyping assay and the HIV-1 home-brew assay. *Journal of Virological Methods* 2009; 159: 211-6.
 43. PA Chan, **R Kantor**. Transmitted Drug Resistance in Non-subtype B HIV-1 Infection. *HIV Therapy* 2009;3:447-465.
 44. N Kumarasamy, V Madhavan, KK Venkatesh, S Saravanan, **R Kantor**, P Balakrishnan, B Devaleenal, S Poongulali, T Yephomi, S Solomon, KH Mayer, C Benson, R Schooley. High Frequency of Clinically Significant Mutations after First Line Generic Highly Active Antiretroviral Therapy Failure: Implications for Second Line Options in Resource Limited Settings *Clinical Infectious Diseases* 2009; 49: 306-309.
 45. S Land, P Cunningham, J Zhou, K Frost, D Katzenstein, **R Kantor**, YMA Chen, S Oka, A DeLong, D Sayer, J Smith, EM Dax, M Law, on behalf of the TREAT Asia network. An External Quality Assessment Scheme Demonstrates High Quality Outcome of HIV Genotypic Resistance Testing in a Group of Asian Laboratories. *Journal of Virological Methods* 2009;159:185-93.
 46. **R Kantor**, L Diero, A DeLong, L Kamle, S Muyonga, F Mambo, W Emonyi, P Chan, EJ Carter, J Hogan, N Buziba. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. *Clinical Infectious Diseases* 2009;49:454-62
 47. M Vidya, S Saravanan, S Uma , N Kumarasamy, SS Solomon, S Solomon, **R Kantor**, D Katzenstein, B Ramratnam, KH Mayer , P Balakrishanan. Genotypic HIV-1 drug resistance among patients failing first-line antiretroviral therapy in south-India. *Antiviral Therapy* 2009;14:1005-9.
 48. Z El-Khatib, AK DeLong, D Katzenstein, AM Ekstrom, J Ledwaba, L Mohapi, F Laher, S Charalambous, A Karstaedt, M Petzold, L Morris, **R Kantor**. Viremia, drug resistance patterns and re-suppression among HIV-1 subtype C patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. *Journal of AIDS and Clinical Research* 2011;2:117.
 49. PA Chan, K Tashima, F Gillani, O Mintz, K Zeller, **R Kantor** Transmitted Drug Resistance and Molecular Epidemiology in Antiretroviral Naïve HIV-1 Infected Patients Presenting to an Outpatient Clinic in Rhode Island. *AIDS Research and Human Retroviruses* 2011;7:275-81.
 50. A Huang, **R Kantor**, A DeLong, L Schreier, S Istrail. QColors: An Algorithm for Conservative Viral Quasispecies Reconstruction from Short and Non-Contiguous Next Generation Sequencing Reads. *Proceedings of Institute of Electrical and Electronics Engineers*

Conference on Bioinformatics and Biomedicine, Workshop on Computational Advances in Molecular Epidemiology; 2011;1:130-136.

51. S Saravanan, V Madhavan, KG Murugavel, P Balakrishnan, SS Solomon, S Umapathy, **R Kantor**, N Kumarasamy, T Yephthomi, DM Smith, KH Mayer, S Solomon. The association between HIV-1 subtype C antiretroviral resistance and HLA prevalence in Southern India. *Journal of AIDS* 2011;57:e17-19.
52. S Saravanan, M Vidya, P Balakrishnan, **R Kantor**, SS Solomon, D Katzenstein, N Kumarasamy, T Yeptomi, S Sivamalar, S Rifkin, KH Mayer, S Solomon. Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India. *Clinical Infectious Diseases* 2011; 54: 995-1000.
53. A DeLong, M Wu, J Wu, J Hogan, **R Kantor**. SQUAT (Sequence Quality Assessment Tool): A standalone computational tool for HIV sequence quality evaluation. *AIDS Research and Human Retroviruses* 2012;28:894-901.
54. A Huang, J Hogan, S Istrail, A DeLong, D Katzenstein, **R Kantor**. Global Analysis of Sequence Diversity Within HIV-1 Subtypes Across Geographic Regions. *Future Virology* 2012;7:505-17
55. S Saravanan, V Madhavan, SS Solomon, **R Kantor**, D Katzenstein, S Sivamalar, N Kumarasamy, DM Smith, KH Mayer, S Solomon, P Balakrishnan. Reverse Transcriptase Substitution at Codons 208 and 228 Among Treatment-experienced HIV-1 Subtype-C Infected Indian Patients Is Strongly Associated with Thymidine Analogue Mutations. *Journal of AIDS*, 2012;59:e26-7.
56. S Saravanan, M Vidya, **R Kantor**, S Sivamalar, S Gomathi, SS Solomon, N Kumarasamy, DM Smith, RT Schooley, S Solomon, P Balakrishnan. Unusual Insertion and Deletion at Codon 67 and 69 of HIV Type 1 Subtype C Reverse Transcriptase Among First-Line Highly Active Antiretroviral Treatment-Failing South Indian Patients: Association with Other Resistance Mutations. *AIDS Research and Human Retroviruses* 2012, May 21 (Epub ahead of print).
57. B Westley, AK Delong, CS Tray, D Sophearin, EM Dufort, E Nerrienet, L Schreier, JI Harwell, **R Kantor**. Prediction of Treatment Failure using 2010 WHO Guidelines is Associated with High Misclassification Rates and Drug Resistance among HIV-Infected Cambodian Children *Clinical Infectious Diseases*, 2012;55:432-440.
58. NE Alexander, PA Chan, T Rogo, Z Parillo, C Browning, B Isabell, C Calcione, S Chowdhury, P Simon, **R Kantor**. Interrupting Transmission of HIV and other Sexually Transmitted Infections in Rhode Island. *Medicine and Health RI* 2012;95:241-244.
59. PA Chan, A Huang, **R Kantor**. Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: Implications for pre-exposure prophylaxis. *Journal of the International AIDS Society* 2012;15:17701.
60. A Jiamsakul, **R Kantor**, PCK Li, S Sirivichayakul, T Sirisanthana, P Kantipong, CKC Lee, A Kamarulzaman, W Ratanasuwana, R Ditangco, T Singtoroj, S Sungkanuparph Comparison of Predicted Susceptibility between Genotype and Virtual Phenotype HIV Drug Resistance Interpretation Systems among Treatment-naive HIV-infected Patients in Asia: TASER-M Cohort Analysis. *BMC Research Notes* 2012;5:582.
61. PA Chan, S Kazi, A Rana, I Blazar, CC DeJong, KH Mayer, TK Huard, K Carleton, F Gillani, N Alexander, Z Parillo, TP Flanigan, **R Kantor**. New HIV infections at Southern New England academic institutions: Implications for prevention (in press, *AIDS Research and Human Retroviruses*).
62. A Huang, **R Kantor**, A DeLong, L Schreier, S Istrail. QColors: An Algorithm for Conservative Viral Quasispecies Reconstruction from Short and Non-Contiguous Next Generation Sequencing Reads (in press, *In Silico Biology*).
63. S Saravanan, V Madhavan, P Balakrishnan, DM Smith, SS Solomon, S Sivamalar, S Poongulali, N Kumarasamy, RT Schooley, S Solomon, **R Kantor**. Darunavir is a good third-line antiretroviral agent for HIV-1 infected patients failing second-line protease inhibitor-based regimens in South India (in press, *AIDS Research and Human Retroviruses*).